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Tumour invasion and metastasis is a multistep process that
requires loss of growth control, tumour cell locomotion and attach-
ment, proteolysis of the extracellular matrix (ECM) and tumour
cell colony formation in the target organ for metastasis (Stetler-
Stevenson et al, 1993). Proteolysis of the ECM is principally
mediated by two classes of enzymes: members of the plasminogen
activator/plasmin system and the matrix metalloproteinase (MMP)
family. The MMPs include 16 structurally related, zinc-dependent
endopeptidases that are divided into subfamilies of collagenases,
stromelysins, gelatinases, membrane-type MMPs and novel
MMPs according to their structure and substrate specificity
(Birkedal-Hansen et al, 1993; Llano et al, 1997; Pendas et al,
1997). The active enzymes are specifically inhibited by TIMPs
(tissue inhibitor of metalloproteinases). As a group, MMPs are
capable of degrading essentially all components of the ECM, and
increased MMP activity has been correlated with the progression
of malignant tumours of various origins, including the lung,
prostate, breast, colon and skin (reviewed by Stetler-Stevenson
et al, 1993).
Malignant melanomas are highly invasive and metastatic
tumours that are becoming increasingly prevalent worldwide. The
most important prognostic factors in patients without metastases
are the level of invasion and tumour thickness. The depth of inva-
sion can be classified to various histological levels according to
Clark et al (1969), whereas Breslow (1970) measures tumour
thickness from the top of the epidermal granular layer to the
deepest extension of the tumour. Other factors contributing to
unfavourable prognosis include lymph node metastases, axial
location, male sex, high age, wide diameter of the lesion and ulcer-
ation (Lever and Schaumburg-Lever, 1990).
Overexpression of 72-kDa (MMP-2) and 92-kDa (MMP-9)
gelatinases has been correlated with the invasive phenotype in both
melanoma cell lines and melanoma cells in vivo (Höyhtyä et al,
1990; Montgomery et al, 1993; McDougall et al, 1995; Brooks et
al, 1996; Väisänen et al, 1996). Expression of collagenase-1
(MMP-1) and stromelysin-1 (MMP-3) has also been reported in
metastatic melanoma cell lines (Brown et al, 1990; Montgomery
et al, 1993). Recently, invasion of melanoma cells through type I
and IV collagens and matrigel was shown to be suppressed by anti-
sense RNA for MMP-1 (Durko et al, 1997). The ability of TIMP-1
and -3 to inhibit tumour growth has been observed by overex-
pressing these MMP-inhibitors in melanoma cell lines (Khokha,
1994; Anand-Apte et al, 1996). According to a recent report,
TIMP-2 overexpression reduces the invasion and angiogenesis-
inducing properties of some melanoma cells in vivo and protects
them from apoptosis (Valente et al, 1998). Furthermore, TIMP-2 is
important in melanoma biology in the MMP-2 activation cascade.
MT1-MMP (MMP-14) binds TIMP-2 specifically, generating an
MTI-MMP–TIMP-2 complex, which, in turn, functions as a
receptor for the MMP-2 proenzyme (Strongin et al, 1995; Butler et
al, 1998).
We have previously found that expression of the novel MMP,
collagenase-3 (MMP-13), is up-regulated during malignant trans-
formation of non-melanoma skin tumours (Airola et al, 1997;
Johansson et al, 1997). Both MMPs-1 and -13 efficiently degrade
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Summary Since proteolysis of the dermal collagenous matrix and basement membranes is required for local invasive growth and early
metastasis formation of cutaneous melanomas, we have analysed the activities/expression levels of certain metalloproteinases in melanomas
and cultured melanoma cells by in situ hybridization and Northern analysis. In addition to collagenases-1 and -3 that have been implicated in
invasive growth behaviour of various malignant tumours, we analysed the levels of 72-kDa gelatinase and its activators MT1-MMP and TIMP-
2 in cultured melanoma cells. The lesions examined included three cases of lentigo maligna and 28 cases of Clark grade I–V melanomas. The
premalignant as well as the grade I tumours were consistently negative for collagenase-1 and -3 and TIMP-1 and -3. The collagenases were
predominantly expressed in the cancer cells of Clark grade III and IV tumours. TIMP-1 and -3 were abundantly expressed in the cancer and/or
stromal cells of grade III and IV melanomas, while TIMP-2 protein was detected also in melanomas representing lower invasive potential.
Northern analysis of seven melanoma cell lines showed that the expression of collagenase-1 and TIMPs-1 and -3 was associated with
72-kDa gelatinase positivity. All melanoma cell lines were positive for MTI-MMP and TIMP-2 mRNAs. Our results suggest that overexpression
of collagenases-1 and -3 and TIMPs -1 and -3 is induced during melanoma progression. Expression of TIMPs may reflect host response
to tumour invasion in an effort to control MMP activity and preserve extracellular matrix integrity.
Keywords: MMP; cell invasion; angiogenesis; gelatinase
733
British Journal of Cancer (1999) 80(5/6), 733–743
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0417
Received 10 September 1998
Revised 3 December 1998
Accepted 3 December 1998
Correspondence to: UK Saarialho-Keretype I, II and III collagens. Furthermore, MMP-13 is gelatinolytic
and type IV collagenolytic (Knäuper et al, 1996, 1997), and MMP-
1 has also some activity against full-length type IV collagen
(Collier et al, 1988). Our objective was to determine the expres-
sion patterns and cellular localization of these MMPs during
melanocytic tumour progression. Furthermore, as imbalance
between TIMPs and MMPs is an important factor in tumour inva-
sion, the expression levels of collagenase inhibitors TIMP-1 and
-3 were also examined. Our results suggest that the induction of
MMPs-1 and -13 and their tissue inhibitors is a late event in
melanocytic tumour progression, and that these enzymes are
involved in the regulation of melanoma invasion.
MATERIALS AND METHODS
Tissue specimens
Formalin-fixed, paraffin-embedded specimens were obtained from
the Department of Dermatopathology, Helsinki University Central
Hospital, Helsinki, Finland. Invasion levels of the melanomas were
determined by Clark’s classification: level I with confinement of
the malignant melanoma cells to the epidermis and its appendages;
level II with extension to the papillary dermis so that only a few
melanoma cells extended to the interface between the papillae and
reticular dermis; level III with filling the papillary dermis until the
boundary between the papillary and the reticular dermis; level IV
with invasion of the reticular dermis; and level V with invasion
of the subcutaneous fat (Clark et al, 1969). Furthermore, tumour
thickness was measured according to Breslow (tumours less than
0.76 mm thick represent low metastatic risk while those more than
1.5 mm are of high risk; Breslow, 1970). The samples included
three lentigo malignas, four grade I, five grade II, nine grade III,
nine grade IV and one grade V malignant melanomas, as assessed
by an experienced dermatopathologist (A-LK).
RNA probes
The production and specificity of the 550-bp MMP-1, 490-bp
MMP-13, 313-bp TIMP-1 and 635-bp TIMP-3 antisense probes
have been described earlier in detail (Saarialho-Kere et al, 1992;
Johansson et al, 1997; Airola et al, 1998). The cDNAs were tran-
scribed in vitro using a commercial kit (Promega Corp., Madison,
WI, USA) and labelled with 35S-UTP, as previously described
(Saarialho-Kere et al, 1993).
cDNA probes
Full-length human cDNA for MMP-2 was given by Dr G
Goldberg, Department of Dermatology, Washington University
(Collier et al, 1988). A 699 bp cDNA probe corresponding to
bases 884–1582 of MT1-MMP sequence was generated by reverse
transcription polymerase chain reaction (RT-PCR) from HT-1080
cDNA (Lohi and Keski-Oja, 1995). A 537 bp cDNA fragment was
used for detecting TIMP-2 (provided by Dr G Goldberg). Rat
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA
(Forth et al, 1985) was used to standardize the loading of RNA.
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Table 1 Characteristics of patients and expression of MMPs and TIMPs in cutaneous melanomas
Clark Breslow Subtype Sex/age Loc/Metast. MMP-1 MMP-13 TIMPs MMP-2 MT1-MMP
(mm)
-1 -3 -2
I n.d. ss F/63 Palm/no – – – – +ca,s –
I n.d. ss F/50 leg/n.d. – – – – – – –
I n.d. ss F/27 leg/no – – – – +ca +ca,s –
I 0.4 ss M/58 side/no – – – – +s
II 0.2 ss M/52 chest/no – – – – – +s
II 0.3 ss M/51 shoulder/no – – – – +ca,s ++s ++s
II 0.4 ss F/25 chest/no – – – – ++s +s
II 0.45 ss M/53 neck/n.d. +ca – – – +s – –
II 0.5 ss F/28 back/n.d. – – +s – ++ca,s – –
III 0.6 ss F/78 face/no – – – –
III 0.7 ss M/45 chest/no +ca – – – +ca,s
III 0.7 ss F/55 leg/n.d. +ca +ca +++ca,s +s +s +s
III 0.9 n F/36 ear/n.d. ++ca – +ca,s +ca,s +s +s
III 0.95 ss M/59 back/no – – – – – –
III 1.1 ss F/44 back/no – – – –
III 1.7 n F/57 arm/yes – – ++ca +ca
III 2.0 n F/79 face/no +ca +ca +s – +s
III 2.6 n M/39 abdomen/no +++ca +ca +++ca,s ++ca,s
IV 2.1 n M/58 back/yes ++ca +++ca +++ca +++ca +s +s +s
IV 2.7 n M/93 ear*/no – – +++ca,s ++ca,s
IV 2.4 ss M/51 genitals/no +ca – +ca (+)ca +ca (+)ca +ca,s
IV 3.0 n M/71 arm/no +ca (+)ca +ca,s (+)s ++ca – +ca
IV 3.5 n M/86 leg*/no +s – +++s ++s +ca
IV 3.5 n M/62 neck/no ++ca +ca +s ++ca,s ++s +s +ca,s
IV 4.0 n F/33 back/no – – ++ca,s
IV 5.0 n M/74 back*/n.d. – – +s +ca,s ++ca,s ++s ++s
IV 6.0 n F/83 arm*/n.d. ++ca ++ca +++ca,s +ca
V 6.5 n F/84 arm/no +ca – +ca (+)ca ++ca +s
ss: superficially spreading; n: nodular; n.d.: not determined; ca: expression in tumour cells; s: expression in stromal cells; *ulcerated tumourCollagenases and TIMPs in melanoma 735
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Figure 1 Expression of MMPs-1 and -13 by melanoma cells adjacent to the stroma. (A) Dark-field image of MMP-1 mRNA in tumour cells (arrows) of grade III
melanoma (magnification 100 ´) and (B) high magnification (400 ´) of the MMP-1 positive cells. (C) Another area of the same tumour (200 ´). Note the
collagenous stroma adjacent to the MMP-1 expressing cells (arrows). (D) Corresponding bright-field image. (E) MMP-13 mRNA in tumour cells (arrows) of
grade IV melanoma. (F) Higher magnification of the MMP-13-positive cells. (G) Same specimen hybridized with MMP-1 probe, indicating differential localization
of expression of the two collagenases. Open arrows depict corresponding locations (E, G). Scale bar: A, 40 mm; C, D, E, 20 mm; B, F, 10 mmIn situ hybridization
Following deparaffinization and rehydration, sections were
pretreated with 1 mg ml–1 of proteinase K and washed in 0.1 M
triethanolamine containing 0.25% acetic anhydride. Subsequently,
sections were hybridized with probes (2.5–5 ´ 104 cpm ml–1 of
hybridization buffer) and washed under stringent conditions,
including treatment with RNAase, as described (Saarialho-Kere
et al, 1993). Autoradiography was carried out for 10–30 days. All
samples were processed in at least two experiments, and were
independently examined by two experienced investigators. The
signals were scored arbitrarily as follows: (–) no detectable signal,
(+) specific signal in a few cells, (++) specific signal in a moderate
number of cells, and (+++) specific signal in a high number of
cells.
Immunohistochemistry
Immunostaining was performed using the avidin–biotin–
peroxidase complex technique (Saarialho-Kere et al, 1993).
Aminoethylcarbazole was used as chromogenic substrate.
Monoclonal antibodies included anti-MMP-2 (clone 42-5D11,
Oncogene Research Products, Cambridge, MA, USA), anti-MT1-
MMP (clone 114-6G6, Oncogene Research Products) and anti-
TIMP-2 (clone 67-4H11, Fuji Chemicals, Japan). The tissues were
counterstained with haematoxylin and controls were performed
with pre-immune mouse ascites fluid.
Cell cultures and Northern hybridization analysis
The majority of the melanoma cell lines have been isolated from
melanoma metastases and most of them were established at the
Wistar Institute (WM, Wistar melanoma). Human fibrosarcoma
HT-1080 cells (CCL-121, American Type Culture Collection,
Rockville, MD, USA) and melanoma cell lines Bowes, G361,
WM793, WM852, WM164, WM165 and WM239 were cultivated
in Eagle’s minimal essential medium (MEM) (Gibco BRL,
Gaithersburg, MD, USA), containing 10% heat inactivated fetal
calf serum, 100 IU ml–1 penicillin, and 50 mg ml–1 streptomycin.
Confluent cultures were incubated under serum-free conditions for
6 h and subsequently with 40 nM PMA (phorbol myristate acetate)
for 24 h as indicated. RNA was purified by the guanidium thio-
cyanate method (Chomczynski and Sacchi, 1987), and 15 mg of
total RNA was electrophoresed on a 0.8% formaldehyde-agarose
gel and transferred to a Zeta probe filter (Bio-Rad, Richmond, CA,
USA) and immobilized by UV cross-linking. The filters were
hybridized to probes labelled with 32P-dCTP (Amersham) by the
random priming method (Pharmacia LKB, Uppsala, Sweden).
Hybridization (42°C, 24 h) and subsequent washing were
performed under stringent conditions. Stripping, when needed,
was performed in 0.1 ´ saline–sodium citrate (SSC), 0.5% sodium
dodecyl sulphate (SDS) at 100°C for 10 min.
Assays for gelatinolytic activity
Conditioned media from HT-1080 and melanoma cells were
assayed by gelatin zymography essentially as described (Lohi et
al, 1992). Samples of conditioned medium were dissolved in non-
reducing Laemmli sample buffer and separated by electrophoresis
using discontinuous 3.5:7% polyacrylamide gels containing 1 mg
ml–1 gelatin (Laemmli, 1970). After electrophoresis the gels were
washed twice with 50 mM Tris–HCl buffer pH 7.6, containing 5
mM calcium chloride, 1 mM zinc chloride, 2.5% Triton X-100 (v/v)
for 15 min to remove SDS, followed by brief rinsing in washing
buffer without Triton X-100. The gels were incubated at 37°C for
1–2 days in 50 mM Tris–HCl buffer containing 5 mM calcium
chloride, 1 mM zinc chloride, 1% Triton X-100, 0.02% NaN3, pH
7.6. The digestion was terminated by 10% acetic acid followed by
staining with Coomassie brilliant blue R250 and destaining with
10% acetic acid, 10% methanol. Zones of enzymatic activity were
seen as negatively stained bands.
Reversed gelatin zymography
Samples of HT-1080 and melanoma cells were treated as described
above (assays for gelatinolytic activity). Aliquots of concentrated
conditioned medium (corresponding to the amount secreted by 104
cells) were analysed by electrophoresis using discontinuous 4:12%
polyacrylamide gels containing 0.7 mg ml–1 gelatin and 35 ng ml–1
72-kDa gelatinase (Chemicon International, Inc., Temecula, CA,
USA). After electrophoresis the gels were washed, incubated for
40–50 h, stained and destained as described above (assays for
gelatinolytic activity).
RESULTS
MMPs-1 and -13 are expressed by invasive melanoma
cells
To assess whether MMPs -1 and -13 and TIMPs -1 and -3 are
expressed in melanomas in vivo, 28 samples were studied using in
situ hybridization. Lentigo malignas and grade I tumours were
consistently negative for both MMP-1 and -13 mRNA, while 1/5
grade II, 5/9 grade III, and 6/9 grade IV tumours expressed MMP-
1 (Table 1). MMP-13 mRNA was detected in 3/9 grade III and 4/9
grade IV tumours (Table 1). Both collagenases were expressed by
tumour cells (Figure 1). MMP-1 mRNA was more abundant and
detected specifically at the edges of tumour nodules that were
surrounded by areas of connective tissue (Figure 1 C,D), while
MMP-13 mRNA was detected more centrally within the tumour
(Figure 1 E,F). Generally, tumour front facing the dermis was
negative for both collagenases.
TIMPs-1 and -3 are abundantly expressed in grade III
and IV melanomas
Since the activity of collagenases is effectively controlled and
locally restricted by TIMPs, we analysed next the expression of
TIMPs-1 and -3 in the specimens. TIMP-1 and -3 mRNAs were
frequently detected in the grade III and IV melanomas in both
tumour and stromal cells (Table 1). Five of nine of grade III, 9/9 of
grade IV tumours and 1/1 grade V tumour expressed TIMP-1
mRNA, and 4/9 of grade III, 8/9 of grade IV and 1/1 grade V
tumours TIMP-3 mRNA. TIMP-1 expression was more abundant
at the tumour-stromal front (Figure 2 A–D). In addition to tumour
cells and fibroblasts, TIMP-3 mRNA was detected in endothelial
cells within connective tissue septae (Figure 2 E,F). Only two of
the tumours had metastasized during the follow-up period (1–7
years). No follow-up information was available from seven out of
28 patients (Table 1). The mRNA expression patterns of collage-
nases or TIMPs did not reveal any clear differences between the
metastasized and localized tumours (Table 1).
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To verify the ability of melanoma cells to express collagenases and
TIMPs in cell culture, seven different human melanoma cell lines
(see Figure 3 for details) were grown to confluency, changed to
serum-free culture medium and treated with PMA (40 mM) for 24 h
followed by RNA extraction and Northern hybridization analysis.
MMP-1 mRNA was expressed in 3/7 (Figure 3) unstimulated cell
lines, all of which also expressed MMP-2 abundantly. No MMP-13
mRNA was detected, whereas control human lung fibroblasts
(CCL-137) and HaCaT keratinocytes expressed detectable levels of
this enzyme (data not shown). All TIMPs were frequently
expressed: TIMP-1 and -2 in 7/7 and TIMP-3 in 5/7 cell lines.
Expression of TIMP-1 was, however, more abundant than that of
TIMP-3. Treatment of the cells by PMA generally stimulated MMP
and TIMP expression (Figure 3).
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Figure 2 Expression of TIMP-1 and -3 mRNAs. (A) TIMP-1 mRNA in tumour cells (arrows) and stromal cells (open arrows) in grade III melanoma. (B) Higher
magnification bright-field of the same specimen. (C) Grade IV melanoma with abundant signal for TIMP-1 mRNA in tumour cells (arrows) at the tumour-stromal
front. (D) Higher magnification bright-field of the tumour front facing dermis. (E) Dark-field image of TIMP-3 mRNA expression in grade IV tumour (arrow =
stromal cell, open arrow = tumour cell). (F) High-power bright-field image of TIMP-3-expressing cells. Arrows indicate endothelial cells within connective tissue
septae. Scale bar: A, C, E, 40 mm; D, F, 20 mm; B, 10 mmMT1-MMP and MMP-2 are expressed by cultured
melanoma cells
Overexpression of MT1-MMP has been associated with invasive-
ness of cancer cells, evidently via activation of MMP-2 (Sato et al,
1994). The levels of MT1-MMP mRNA in melanoma cell lines
were therefore assayed by Northern hybridization. HT-1080
human fibrosarcoma cells were used as a control (Lohi et al,
1996). MT1-MMP was expressed at a considerable level in all
melanoma cell lines and in four cell lines (WM239, WM793,
WM852 and WM164) its expression was increased about twofold
by PMA (Figure 3). mRNA levels of MMP-2 were exceptionally
high in some melanoma cell lines (WM239, WM793, WM852 and
WM165), while in three other melanoma cell lines (G361,
WM164, Bowes) MMP-2 was expressed at a level comparable to
that of HT-1080 cells (Figure 3). Interestingly, the cell lines G361
and WM164, that were negative for both MMP-1 and -2 mRNAs,
have been established from primary non-metastatic melanoma cell
lines (Peebles et al, 1980; Iliopoulos et al, 1989). Cell lines
expressing both MMP-1 and -2 (WM239, WM165, ML852) have
been established from melanoma metastases (Herlyn et al, 1985a,
1985b). However, since Bowes cell line established from a
metastatic melanoma (Opdenakker et al, 1983; Rifkin DB,
personal communication) was MMP-1 negative and WM793
grown from human primary melanoma (Herlyn et al, 1985b) posi-
tive for both MMPs-1 and -2, no fully consistent conclusions
between MMP-1 and -2 positivity and invasiveness can be drawn.
TIMP-2 protein is expressed in melanomas independent
on their Clark classification
Based on our results on melanoma cell lines, we also conducted an
immunohistochemical study for MMP-2, MT1-MMP and TIMP-2
in a subset of melanomas, including samples from all Clark grades
(Table 1). TIMP-2 protein was expressed in stromal (fibroblasts
and endothelial cells in cancer stroma and surrounding the tumour)
or cancer cells in 17/19 samples (Figure 4 A–C) and, unlike
TIMPs-1 and -3, its expression was abundant also in melanomas
with low invasive potential (Table 1). MMP-2 protein was
detected mainly in stromal cells bordering the tumour in 9/15
samples (Figure 4D). MT1-MMP was most abundantly expressed
in cancer cells of Clark grade IV tumours (Table 1; Figure 4 E,F).
Melanoma cells secrete MMP-2 in latent form
To correlate the MT1-MMP expression to MMP-2 activation,
culture medium of melanoma cells and HT-1080 cells from a
similar experiment were analysed by gelatin zymography.
Untreated HT-1080 cells produced, in addition to MMP-9, the
MMP-2 mainly in the latent form. It was efficiently processed to
the active 62-kDa form in cultures treated with PMA (Figure 5A).
On the contrary, all melanoma cell lines secreted MMP-2 in latent
form only, and no lower molecular weight forms corresponding to
the activated 62-kDa form were seen, even in the culture medium
of cells treated with PMA (Figure 5A).
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 HT-1080  WM 239      G 361     WM 793   WM 852   WM 164    WM 165   Bowes
+              +                 +              +               +              +              +               + PMA:
MMP-2
MMP-1
MT1-MMP
TIMP-1
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Figure 3 Northern hybridization analysis for MMP-2, MMP-1, MT1-MMP, TIMP-1, -2 and -3 mRNAs in HT-1080 and the different melanoma cell lines
(designations given on the Figure) treated with PMA as indicated for 24 h. Because of the variation of the levels of MMP-2 mRNA some cell lines appear
negative in this exposure. Longer exposures gave faint bands indicating that MMP-2 is expressed in all melanoma lines studied (compare with zymographic
analysis). GAPDH mRNA levels served as internal standardCollagenases and TIMPs in melanoma 739
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Figure 4 Immunostaining for TIMP-2 is positive in invasive melanoma cells (arrows) in Clark grade I (A) and IV (B) melanomas. (C) TIMP-2 staining is
detected in fibroblasts and endothelial cells inside the tumour in the same specimen. (D) MMP-2 protein is detected in fibroblasts in the stroma surrounding the
tumour. (E) Clark grade IV melanoma with positive immunostaining for MT1-MMP in melanoma cells at the invasive front of the tumour (arrows). (F) A higher
magnification of MT1-MMP positive cells inside the tumour. (G) Negative control. AEC was used as chromogenic substrate and haematoxylin as counterstain.
Scale bar: A, B, C, D, F, 20 mm; E, G, 40 mm
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To analyse the levels of TIMP-1 and -2 in the melanoma cell lines,
we carried out reverse zymography assays (see Methods). All
melanoma cell lines produced TIMP-1 and -2 (Figure 5B). The
levels of TIMP-1 (31 kDa) were slightly more clearly inducible by
PMA than the levels of TIMP-2 (21 kDa). The levels of the TIMPs
were relatively low in control HT-1080 cells. All melanoma lines
except Bowes secreted also gelatinase inhibitory activity of 25–27
kDa, most probably corresponding to TIMP-3. This was
inducible by PMA treatment (Figure 5B).
DISCUSSION
Proteolytic activity produced either by tumour cells or surrounding
stromal cells is fundamental to invasion and metastasis of malig-
nant tumours, including melanomas. Expression of gelatinases
and members of the plasminogen activator/plasmin system, in
particular, has been proposed to contribute to the aggressive and
metastatic growth of malignant melanomas (Mueller, 1996). In
this work we observe that melanoma cells express MMPs-1, -2,
-14 and TIMPs-1, -2 and -3 both in vivo and vitro. To our knowl-
edge, this is the first report on the tissue localization of MMPs-1
and -13 as well as TIMPs-1, -2 and -3 in cutaneous malignant
melanomas. We describe that the induction of MMPs-1 and -13
and their tissue inhibitors is a late event in melanocytic tumour
progression, and correlates with the invasion of cutaneous
melanomas in vivo. These results substantiate the role of collagen-
ases in melanoma invasion, and demonstrate that high levels
of TIMP expression paradoxically associate with an advanced
tumour stage and subsequent poor prognosis.
MMP-1 is frequently expressed by stromal cells of non-
melanoma skin cancers (Kähäri and Saarialho-Kere, 1997). MMP-
13 was originally cloned from human breast carcinomas (Freije et
al, 1994), and the mRNA is expressed predominantly in tumour
cells of squamous cell carcinomas of the head and neck and basal
cell carcinomas (Airola et al, 1997; Johansson et al, 1997). In
contrast to frequent overexpression of MMP-1 in the stroma of
various cancers, both collagenases were produced by malignant
melanoma cells themselves. In melanomas, the production of
MMPs-2 and -9 has been reported during the initial radial growth
phase and during early invasive phase, as the tumour cells penetrate
the basement membrane and migrate into the papillary dermis
(Väisänen et al, 1996; van den Oord et al, 1997). In contrast,
members of the plasminogen activator/plasmin system are predom-
inantly expressed during the highly invasive vertical growth phase
(de Vries et al, 1994), similarly to MMPs-1 and -13. It is likely that
temporally and spatially differentially regulated expression of
proteinases allows selective degradation of ECM proteins and effi-
cient tumour cell migration. Thus, expression of multiple invasion-
associated proteinases may represent an important feature of a
tumour that has acquired the ability for metastatic growth.
Expression of neither collagenases nor TIMPs could be associ-
ated with clinical metastases, since only two tumours had metasta-
sized during the follow-up period. However, expression of MMP-1
by tumour cells adjacent to connective tissue septae containing
blood vessels may be associated with early metastatic events, e.g.
tumour cell migration towards the vessel wall. The role of MMP-
13, produced by individual, centrally located tumour cells, may be
equally associated with proteolytic degradation of the connective
tissue. Alternatively, MMP-13 may be involved in other processes
such as apoptosis, as demonstrated previously in basal cell carci-
nomas (Airola et al, 1997). In contrast to the in vivo results, none
of the melanoma cell lines tested expressed MMP-13. As demon-
strated by Uria et al (1997) by using co-cultures of fibroblasts and
breast cancer cell lines, interactions between both cell types are
essential in modulating MMP-13 expression by human fibroblasts.
This suggests that expression of MMP-13 may require the collab-
oration of several cell types and thus lack of stromal cells or the
different pericellular environment may explain the absence of
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Figure 5 (A) Cultured melanoma cells secrete only the latent form of MMP-2. Confluent cultures of HT-1080 and melanoma cells were treated with PMA under
serum-free conditions for 24 h as shown in the Figure (see Methods). Aliquots of conditioned medium (corresponding to the amount secreted by 104 cells for
melanomas and 5 ´ 104 cells for HT-1080) were analysed by gelatin zymography using 7% SDS-PAGE. The level secreted by Bowes cells was barely
detectable (in accordance with Northern analysis) but positive. (B) All melanoma cell lines produce TIMP-1 and -2, the levels of TIMP-1 being more inducible by
PMA than the levels of TIMP-2. Aliquots of concentrated conditioned medium from cells incubated with or without PMA were analysed by reversed gelatin
zymography. An arrow indicates the migration of a third TIMP activity band, probably corresponding to TIMP-3
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AMMP-13 in melanoma cell lines. The number of cells containing
MMP-13 mRNA in the lesions studied was clearly smaller than
those having signal for collagenase-1 or TIMPs. Nevertheless, the
in vivo data presented here promotes the association of MMP-13
expression with malignant transformation.
The expression of TIMPs-1 and -3 was associated with progres-
sive invasion in malignant melanomas. Since angiogenesis is
required for expansion of solid tumours, the enhanced expression
may be related to the anti-angiogenic activity reported for both
inhibitors (Johnson et al, 1994; Anand-Apte et al, 1997).
Expression of TIMP-3 in endothelial cells within the tumour
supports this hypothesis. Interestingly, in vivo overexpression of
TIMP-3 in certain melanoma cell lines is associated with apoptosis
(Ahonen et al, 1998) and we cannot exclude that some TIMP-3
mRNA positive tumour cells were actually undergoing
programmed cell death. TIMP-1 was predominantly expressed
at the invasion front, suggesting rather a role in inhibition of
proteolysis at the advancing tumour edge. Since MMP-1 and -13
mRNAs were not frequently detected at this area, the inhibitory
activity of TIMP-1 may be directed towards other proteinases,
such as stromelysins or MMP-9.
It has been proposed that the cell surface concentrations of
TIMPs are crucial for the ability of MT1-MMP to activate MMP-
2. In HT-1080 fibrosarcoma cells we have observed efficient
processing of MT1-MMP and activation of MMP-2 in response to
PMA (Lohi et al, 1996; Lehti et al, 1998). The levels of TIMPs
were low in the conditioned medium of HT-1080 cells, while they
were clearly seen in the melanomas. TIMP-1 was especially
prominent, but it is not known to participate in or interfere with
MMP-2 activation. TIMP-2 levels were slightly inducible by
PMA, as well as TIMP-3.
We have attempted to correlate here also the expression of
certain MMPs and their inhibitors to those of established cell lines.
We observed expression of MT1-MMP, MMP-2 and TIMPs-1, -2
and -3, which was in most cases induced by the phorbol ester
PMA. Expression of MMP-13 was, however, not noted. The corre-
lation remained thus inconclusive. This is probably due to several
reasons. Cultivation is known to affect the expression of several
genes and to select subpopulations of cells that may not reflect the
status of the original tumour. In addition, the connective tissue as
well as inflammation characteristics of melanomas, are missing
from the surroundings of cultured cells, which modifies the
expression of MMPs.
MT1-MMP is able to cleave type I–III collagens, gelatin,
fibronectin and laminin and to activate MMP-13 (Murphy and
Knäuper, 1997). Its enhanced expression in various tumours
suggests that MT1-MMP is an important enzyme in cell invasion.
Lack of MMP-2 activation even in those melanoma cell lines,
which express high levels of MT1-MMP, suggests that in culture
these cells may need some exogenous factors like TIMP-2 or
contact with e.g. collagen for MMP-2 activation (Strongin et al,
1995; Butler et al, 1998). We found that TIMP-2 was expressed at
a fairly similar level in all melanoma cell lines and HT-1080 cells
(Figure 3). Consequently, lack of MMP-2 activation by melanoma
cell lines cannot be attributed to differential regulation of TIMP-2
expression. On the other hand, cultured melanoma cells may not
possess the capability present in in vivo melanomas because of
different pericellular environment and lack of stromal cells. Our
previous results (Lohi et al, 1995) indicate that although over-
expression of MT1-MMP is in some cell lines enough to induce
MMP-2 activating activity, the expression of MT1-MMP per se is
not sufficient to cause this.
No previous histological data are available on the expression of
MT1-MMP and TIMP-2 in melanocytic tumours. Väisänen et al
(1996) detected MMP-2 immunoreactivity in 50% of their
melanomas. We found MMP-2 mostly in stromal cells, which may
be explained by a limited number of cases analysed as well as
different antibodies. TIMP-2 was detected in melanoma cells,
fibroblasts or in endothelial cells in the majority of tumours
examined, also associated with a low invasion level. MT1-MMP
expression was more often detected in cancer cells in tumours with
high invasive potential. In a recent study on cancer cell types other
than melanoma (Deryugina et al, 1997), cell transfectants charac-
terized by partial MMP-2 activation and relatively low levels of
MMP-2 in its active form were most invasive. This implies that a
balance of MT1-MMP expression, amounts of cell surface-bound
and soluble TIMP-2, levels of TIMP-2-free MMP-2 proenzyme
and activated MMP-2, as well as occupancy of matrix adhesion
receptors, is critical to tumour cells becoming highly invasive.
An imbalance between cell surface associated proteinases and
their inhibitors (higher concentrations of MMPs and lower of
TIMPs) has been traditionally implicated in tumour expansion.
However, increased expression of TIMP-1 and -3 in highly malig-
nant tumours of the gastrointestinal tract and breast has also been
demonstrated (Yoshiji et al, 1996; Airola et al, 1997; Mimori et al,
1997; Powe et al, 1997), in addition to malignant melanomas in this
report. These data raise the question whether TIMPs possess dual
functions in the regulation of tumour growth and invasion. In addi-
tion to suppressing pericellular proteolysis and neovascularization,
they may promote tumour cell proliferation through growth factor-
like activity (Fong et al, 1996; Gomez et al, 1997) at some stage of
tumour progression. Thus, there may be different mechanisms
involved between cancer growth and invasion of early and advanced
melanomas, which requires particular attention when considering
therapeutic intervention with synthetic TIMP analogues.
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